Skip to main content

Table 1 Characteristics of the enrolled patients

From: Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT

  Total n = 17
Age (years) 59.9 ± 11.7 (30–82)
Sex (male/female) 5/ 12
Disease duration (years) 12.7 ± 10.4 (1–41)
Steinbrocker Stage (I/II/III/IV) 2/0/5/10
Steinbrocker Class (1/2/3/4) 2/9/5/1
MTX (%)/dose of MTX (mg/week) 76.5/ 9.3 ± 3.9 (4.0 - 16.0)
PSL (%)/dose of PSL (mg/day) 64.7/ 5.2 ± 3.7 (1.0 - 15.0)
Tacrolimus (%)/dose of tacrolimus (mg/day) 29.4/ 2.3 ± 0.7 (1.5 - 3.0)
  1. MTX: methotrexate, PSL: prednisolone.